- LIXTE Biotechnology Holdings and Liora Technologies recently joined forces to soon offer a real fight against cancer.
- LIXTE develops LB-100, a drug that enhances the effectiveness of cancer treatments, while Liora has developed a unique cancer treatment that’s believed to be more affordable, precise, and efficient than many traditional options.
- Together, this pair of products have incredible clinical and commercial potential, to both help the businesses succeed, while also offering better outcomes for patients suffering from cancer.
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company, and the company’s subsidiary, Liora Technologies, both develop cancer therapies that, when combined, have the potential to improve outcomes and results for cancer patients.
LIXTE’s flagship product and lead clinical candidate is LB-100, which is a proprietary small-molecule inhibitor of protein phosphatase 2A (“PP2A”). Designed to enhance the activity of chemotherapy and immunotherapy, the compound has developed a favorable safety profile in Phase 1 clinical trials and is supported by more than 25 published preclinical and translational studies.
The compound is currently being evaluated in multiple clinical programs that are targeting solid tumors with limited treatment options.
On the other hand, Liora Technologies develops the Linac for Image Guided Hadron Therapy (“LiGHT”) System. This system is a controlled proton therapy platform that offers many benefits over the other proton therapy methods currently available.
It can be deployed rapidly, is much smaller in size than other options, and is cheaper to build and use. The LiGHT System also works more efficiently as it reduces proton loss, allows for much more precise dosing, and allows you to change energy levels in milliseconds, not seconds. Also, the system controls beams electronically, which eliminates the needs for mechanical energy degraders, which often waste a ton of proton energy.
As you could imagine, there’s plenty of synergy between the two products – as the LB-100 enhances cancer therapies by making cancer cells more vulnerable, it takes an already efficient and powerful LiGHT system and makes it even more effective at fighting cancer. In addition to making cancer cells more susceptible to proton therapy and other types of radiation, LB-100 also stops them from being able to effectively recover after being damaged by the radiation.
This synergy not only helps deliver better outcomes for cancer patients, but also the businesses themselves. There aren’t many solutions out there in proton therapy like the LiGHT system, and the platform is a perfect match with LB-100. The combination could potentially be of great use clinically, which in turn boosts the commercial potential of the pairing, as well.
About LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT)
LIXTE Biotechnology Holdings is a clinical-stage pharmaceutical company developing cancer therapies. Instead of introducing standalone treatments, the company focuses on an approach to enhance the effectiveness of established therapies. The company’s work focuses on improving how treatments like chemotherapy and immunotherapy perform in difficult-to-treat cancers.
For more information, visit the company’s website at https://lixte.com.
NOTE TO INVESTORS: The latest news and updates relating to LIXT are available in the company’s newsroom at ibn.fm/LIXT
